As of 2025-07-23, the Intrinsic Value of Guangzhou LBP Medicine Science & Technology Co Ltd (688393.SS) is 22.63 CNY. This 688393.SS valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 32.59 CNY, the upside of Guangzhou LBP Medicine Science & Technology Co Ltd is -30.60%.
The range of the Intrinsic Value is 14.18 - 38.36 CNY
Based on its market price of 32.59 CNY and our intrinsic valuation, Guangzhou LBP Medicine Science & Technology Co Ltd (688393.SS) is overvalued by 30.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (11.09) - (4.03) | (5.94) | -118.2% |
| DCF (Growth 10y) | (0.68) - 0.17 | (0.49) | -101.5% |
| DCF (EBITDA 5y) | 14.18 - 38.36 | 22.63 | -30.6% |
| DCF (EBITDA 10y) | 15.61 - 50.09 | 27.15 | -16.7% |
| Fair Value | 0.12 - 0.12 | 0.12 | -99.63% |
| P/E | 1.08 - 7.33 | 3.75 | -88.5% |
| EV/EBITDA | (3.22) - 15.72 | 3.79 | -88.4% |
| EPV | (0.57) - (1.22) | (0.90) | -102.7% |
| DDM - Stable | 0.19 - 0.65 | 0.42 | -98.7% |
| DDM - Multi | 4.22 - 11.93 | 6.29 | -80.7% |
| Market Cap (mil) | 3,049.45 |
| Beta | 1.63 |
| Outstanding shares (mil) | 93.57 |
| Enterprise Value (mil) | 2,966.45 |
| Market risk premium | 6.13% |
| Cost of Equity | 10.18% |
| Cost of Debt | 5.00% |
| WACC | 10.16% |